PDE2A and central nervous system cancer: As depicted in Figure 2B, PDE2A levels were notably lower in adrenocortical carcinoma (ACC), acute myeloid leukemia (LAML), lower-grade glioma (LGG), ovarian serous cystadenocarcinoma (OV), testicular germ cell tumors (TGCT), and uterine carcinosarcoma (UCS) tissues relative to their corresponding normal tissues.